Emerging anti-inflammatory therapies for atherosclerosis

Current Pharmaceutical Design

Volumn 19, Issue 33, 2013, Pages 5840-5849

  Roubille, François ^a   Kritikou, Ekaterini A ^a   Roubille, Camille ^b   Tardif, Jean Claude ^a,c  

^a MONTREAL HEART INSTITUTE   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atherosclerosis; Colchicine; Coronary disease; Inflammation; Interleukin 1; Leukotriene; P selectin; Serpins; Tumor Necrosis Factor alpha

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; CANAKINUMAB; CERTOLIZUMAB PEGOL; COLCHICINE; CREATINE KINASE MB; ETANERCEPT; FIBROBLAST GROWTH FACTOR; FLUORODEOXYGLUCOSE F 18; GEVOKIZUMAB; GOLIMUMAB; GROWTH DIFFERENTIATION FACTOR 15; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCLACUMAB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LEUKOTRIENE; MATRIX METALLOPROTEINASE; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERINE PROTEINASE INHIBITOR; SERP 1; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ASCENDING AORTA; ASTHMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL FUNCTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CELL PROLIFERATION; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; GRAFT OCCLUSION; HEART INFARCTION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; LOADING DRUG DOSE; MACROPHAGE; NEOINTIMA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PLEIOTROPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAPHENOUS VEIN GRAFT; SMOOTH MUSCLE FIBER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMIC THERAPY; VASCULITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; ENDOTHELIUM, VASCULAR; HUMANS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84883141104     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990351     Document Type: Review

References (128)

1. Small DM. Cellular mechanisms for lipid deposition in atherosclerosis (first of two parts). N Engl J Med 1977; 297: 873-7.
2. Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 2009; 23: 31-40.
3. Newby DE. Triggering of acute myocardial infarction: beyond the vulnerable plaque. Heart 2010; 96: 1247-51.
4. Hiari N, Rudd JH. FDG PET imaging and cardiovascular inflammation. Curr Cardiol Rep 2011; 13: 43-8.
5. Narula J, Garg P, Achenbach S, Motoyama S, Virmani R, Strauss HW. Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med 2008; 5 Suppl 2: S2-10.
6. Ol KK, Agachan B, Gormus U, Toptas B, Isbir T. Cox-2 gene polymorphism and IL-6 levels in coronary artery disease. Genet Mol Res 2011; 10: 810-6.
7. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 2010; 127: 295-314.
8. Erbel C, Dengler TJ, Wangler S, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol 2011; 106: 125-34.
9. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009; 30: 2838-44.
10. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 2005; 112: 1289-95.
11. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-16.
12. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74: 213-20.
13. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
14. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52: 412-20.
15. Duchatelle V, Kritikou EA, Tardif JC. Clinical value of drugs targeting inflammation for the management of coronary artery disease. Can J Cardiol 2012; 28: 678-86.
16. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a populationbased study. Arthritis Rheum 2005; 52: 722-32.
17. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 36-40.
18. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
19. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
20. Moubayed SP, Heinonen TM, Tardif JC. Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol 2007; 18: 638-44.
21. Tardif JC, McMurray JJ, Klug E, et al. Aggressive Reduction of Inflammation Stops Events Trial I. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, doubleblind, placebo-controlled trial. Lancet 2008; 371: 1761-8.
22. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in Creactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-82.
23. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
24. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011. Ann Rheum Dis 2012; 71 Suppl 2: i2-45.
25. Kerekes G, Szekanecz Z, Der H, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008; 35: 398-406.
26. Funayama H, Ikeda U, Takahashi M, et al. Human monocyteendothelial cell interaction induces platelet-derived growth factor expression. Cardiovasc Res 1998; 37: 216-24.
27. Ligresti G, Aplin AC, Zorzi P, Morishita A, Nicosia RF. Macrophage-derived tumor necrosis factor-alpha is an early component of the molecular cascade leading to angiogenesis in response to aortic injury. Arterioscler Thromb Vasc Biol 2011; 31: 1151-9.
28. Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, Kavurma MM. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 2010; 106: 1061-71.
29. Urschel K, Garlichs CD, Daniel WG, Cicha I. VEGFR2 signalling contributes to increased endothelial susceptibility to TNF-alpha under chronic non-uniform shear stress. Atherosclerosis 2011; 219: 499-509.
30. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539-52.
31. Tang V, Dhirapong A, Yabes AP, Weiss RH. TNF-alpha-mediated apoptosis in vascular smooth muscle cells requires p73. Am J Physiol Cell Physiol 2005; 289: C199-206.
32. Takeda R, Suzuki E, Satonaka H, et al. Blockade of endogenous cytokines mitigates neointimal formation in obese Zucker rats. Circulation 2005; 111: 1398-406.
33. Del Porto F, Lagana B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1111-5.
34. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediat Inflamm 2012; 2012: 674265.
35. Szekanecz Z, Kerekes G, Soltesz P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009; 5: 677-84.
36. Wong M, Oakley SP, Young L, et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1277-84.
37. Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1418-23.
38. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012; 25: 644-50.
39. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
40. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-8.
41. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 677-80.
42. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116: 305-11.
43. Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2010; 62: 3145-53.
44. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007; 48: 751-62.
45. Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009; 22: 61-73.
46. Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC. Effects of the TNF alpha Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients with Psoriasis: Results of a Randomized Controlled Trial. Circ Cardiovasc Imaging 2013; 6(1): 83-90.
47. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-9.
48. Lichtman AH, Chin J, Schmidt JA, Abbas AK. Role of interleukin 1 in the activation of T lymphocytes. Proc Natl Acad Sci USA 1988; 85: 9699-703.
49. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-32.
50. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 656-60.
51. Chamberlain J, Evans D, King A, et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol 2006; 168: 1396-403.
52. Dewberry RM, Crossman DC, Francis SE. Interleukin-1 receptor antagonist (IL-1RN) genotype modulates the replicative capacity of human endothelial cells. Circ Res 2003; 92: 1285-7.
53. Nathe TJ, Deou J, Walsh B, Bourns B, Clowes AW, Daum G. Interleukin-1beta inhibits expression of p21(WAF1/CIP1) and p27(KIP1) and enhances proliferation in response to plateletderived growth factor-BB in smooth muscle cells. Arterioscler Thromb Vasc Biol 2002; 22: 1293-8.
54. Isoda K, Shiigai M, Ishigami N, et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation 2003; 108: 516-8.
55. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-61.
56. Wang X, Feuerstein GZ, Gu JL, Lysko PG, Yue TL. Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis 1995; 115: 89-98.
57. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
58. Rajavashisth TB, Xu XP, Jovinge S, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999; 99: 3103-9.
59. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
60. Kamari Y, Werman-Venkert R, Shaish A, et al. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 2007; 195: 31-8.
61. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 100: 2645-50.
62. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000; 191: 303-12.
63. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 1996; 16: 1000-6.
64. Chamberlain J, Francis S, Brookes Z, et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 2009; 4: e5073.
65. Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 2004; 110: 1678-85.
66. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998; 97: 242-4.
67. Merhi-Soussi F, Kwak BR, Magne D, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005; 66: 583-93.
68. Francis SE, Camp NJ, Dewberry RM, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999; 99: 861-6.
69. Kastrati A, Koch W, Berger PB, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000; 36: 2168-73.
70. Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1betamediated diseases. MAbs 2011; 3: 49-60.
71. Roell MK, Issafras H, Bauer RJ, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem 2010; 285: 20607-14.
72. Bhaskar V, Yin J, Mirza AM, et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein Edeficient mice. Atherosclerosis 2011; 216: 313-20.
73. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
74. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5: e78.
75. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214-24.
76. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39-43.
77. Roubille F, Kritikou E, Busseuil D, S. BL, Tardif JC. Colchicine: an old wine in a new bottle? Anti-Inflam Anti-Allergy Agents Med Chem 2013; 12(1): 14-23.
78. Matsukawa A, Yoshimura T, Maeda T, Takahashi T, Ohkawara S, Yoshinaga M. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystalinduced rabbit arthritis. Lab Invest 1998; 78: 559-69.
79. Anderson DC, Wible LJ, Hughes BJ, Smith CW, Brinkley BR. Cytoplasmic microtubules in polymorphonuclear leukocytes: effects of chemotactic stimulation and colchicine. Cell 1982; 31: 719-29.
80. Malech HL, Root RK, Gallin JI. Structural analysis of human neutrophil migration. Centriole, microtubule, and microfilament orientation and function during chemotaxis. J Cell Biol 1977; 75: 666-93.
81. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96: 994-1002.
82. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106: 2894-900.
83. Ben-Chetrit E, Bergmann S, Sood R. Mechanism of the antiinflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford) 2006; 45: 274-82.
84. Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 2007; 56: 3183-8.
85. Wen H, Ting JP, O'Neill LA. A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation? Nat Immunol 2012; 13: 352-7.
86. Tiegs G, Freudenberg MA, Galanos C, Wendel A. Colchicine prevents tumor necrosis factor-induced toxicity in vivo. Infect Immun 1992; 60: 1941-5.
87. Rao P, Falk LA, Dougherty SF, Sawada T, Pluznik DH. Colchicine down-regulates lipopolysaccharide-induced granulocytemacrophage colony-stimulating factor production in murine macrophages. J Immunol 1997; 159: 3531-9.
88. Roberge CJ, de Medicis R, Dayer JM, et al. Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immunol 1994; 152: 5485-94.
89. Manie S, Schmid-Alliana A, Kubar J, Ferrua B, Rossi B. Disruption of microtubule network in human monocytes induces expression of interleukin-1 but not that of interleukin-6 nor tumor necrosis factor-alpha. Involvement of protein kinase A stimulation. J Biol Chem 1993; 268: 13675-81.
90. Nahm DS, Kim HJ, Mah J, Baek SH. In vitro expression of matrix metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and transforming growth factor-beta1 in human periodontal ligament fibroblasts. Eur J Orthod 2004; 26: 129-35.
91. Wesley RB, 2nd, Meng X, Godin D, Galis ZS. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 1998; 18: 432-40.
92. Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Effect of colchicine compared with placebo on high sensitivity Creactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis 2012; 33: 88-94.
93. Nidorf M. Low dose colchicine for secondary prevention of cardiovascular disease (The LoDoCo trial). Special science session. AHA 2012 [Epub ahead of print].
94. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull 1987; 43: 285-96.
95. Salmon JA, Simmons PM, Palmer RM. Synthesis and metabolism of leukotriene B4 in human neutrophils measured by specific radioimmunoassay. FEBS Lett 1982; 146: 18-22.
96. Humes JL, Sadowski S, Galavage M, et al. Evidence for two sources of arachidonic acid for oxidative metabolism by mouse peritoneal macrophages. J Biol Chem 1982; 257: 1591-4.
97. De Caterina R, Zampolli A. From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med 2004; 350: 4-7.
98. Seo KW, Lee SJ, Kim CE, et al. Participation of 5-lipoxygenasederived LTB(4) in 4-hydroxynonenal-enhanced MMP-2 production in vascular smooth muscle cells. Atherosclerosis 2010; 208: 56-61.
99. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998; 97: 2406-13.
100. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-43.
101. Cipollone F, Mezzetti A, Fazia ML, et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 2005; 25: 1665-70.
102. Wong SL, Kearns GL, Kemp JP, et al. Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. Eur J Clin Pharmacol 1998; 54: 715-9.
103. Lehnigk B, Rabe KF, Dent G, Herst RS, Carpentier PJ, Magnussen H. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exerciseinduced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J 1998; 11: 617-23.
104. Tardif JC, L'Allier P. L, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010; 3: 298-307.
105. Lucas A, Liu L, Dai E, et al. The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. Adv Exp Med Biol 2009; 666: 132-56.
106. Richardson J, Viswanathan K, Lucas A. Serpins, the vasculature, and viral therapeutics. Front Biosci 2006; 11: 1042-56.
107. Richardson M, Liu L, Dunphy L, et al. Viral serpin, Serp-1, inhibits endogenous angiogenesis in the chicken chorioallantoic membrane model. Cardiovasc Pathol 2007; 16: 191-202.
108. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-6.
109. Viswanathan K, Bot I, Liu L, et al. Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro. PLoS One 2012; 7: e44694.
110. Nash P, Whitty A, Handwerker J, Macen J, McFadden G. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. J Biol Chem 1998; 273: 20982-91.
111. Dai E, Viswanathan K, Sun YM, et al. Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem 2006; 281: 8041-50.
112. Viswanathan K, Richardson J, Togonu-Bickersteth B, et al. Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. J Leukoc Biol 2009; 85: 418-26.
113. Bot I, von der Thusen JH, Donners MM, et al. Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice. Circ Res 2003; 93: 464-71.
114. Leopold JA. Viral-derived Serp-1 as an adjunctive therapy for percutaneous coronary intervention: another not ready for prime time player? Circ Cardiovasc Interv 2010; 3: 528-30.
115. Tardif JC, L'Allier PL, Gregoire J, et al. A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3: 543-8.
116. Poole JC, Florey HW. Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. J Pathol Bacteriol 1958; 75: 245-51.
117. Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol 2004; 4: 325-35.
118. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-89.
119. Eriksson EE. Intravital microscopy on atherosclerosis in apolipoprotein e-deficient mice establishes microvessels as major entry pathways for leukocytes to advanced lesions. Circulation 2011; 124: 2129-38.
120. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
121. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
122. An G, Wang H, Tang R, et al. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation 2008; 117: 3227-37.
123. Phillips JW, Barringhaus KG, Sanders JM, et al. Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein Edeficient mice. Circulation 2003; 107: 2244-9.
124. Luo W, Wang H, Ohman MK, et al. P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2012; 220: 110-7.
125. Homeister JW, Daugherty A, Lowe JB. Alpha(1, 3)fucosyltransferases FucT-IV and FucT-VII control susceptibility to atherosclerosis in apolipoprotein E-/-mice. Arterioscler Thromb Vasc Biol 2004; 24: 1897-903.
126. Wang H, Zhang W, Tang R, et al. Core2 1-6-N-glucosaminyltransferase-I deficiency protects injured arteries from neointima formation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2009; 29: 1053-9.
127. Huang A, Moretto A, Janz K, et al. Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carbox ylic acid (PSI-421), a Pselectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury. J Med Chem 2010; 53: 6003-17.
128. Chelliah R, Lucking AJ, Tattersall L, et al. P-selectin antagonism reduces thrombus formation in humans. J Thromb Haemost 2009; 7: 1915-9.